Modulation of Diabetes and Dyslipidemia in Diabetic Insulin-Resistant Rats by Mangiferin: Role of Adiponectin and TNF-α

SAMIRA SALEH1,2, NABILA EL-MARAGHY3,4, ENJI REDA2,3 and WALEED BARAKAT3,5

1Cairo University, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kasr El-Aini, Cairo, 11562, Egypt
2October 6 University, Faculty of Pharmacy, Center Axis, Part 1/1, Behind Sixth of October City-Giza Governorate, 12585, 6 October City, Egypt
3Zagazig University, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, 44519, Zagazig, Egypt
4Future University, Faculty of Pharmaceutical Sciences & Pharmaceutical Industries, Al Tagamoa El Khames, Main Center of Town, End of 90th street, 11787, Cairo, Egypt
5Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabuk University, 71491, Tabuk, Kingdom of Saudi Arabia

Manuscript received on April 28, 2014; accepted for publication on August 6, 2014

ABSTRACT
Mangiferin, present in Mangifera indica bark, was reported to produce hypoglycemic and antidiabetic activity in an animal model of genetic type 2 diabetes and in streptozotocin diabetic rats. Its effect on diabetic insulin-resistant animals has not been investigated. The current work aimed to explore the effect of mangiferin on diabetic insulin-resistant rat model. Diabetes was induced by high-fat/high fructose diet for eight weeks followed by a subdiabetogenic dose of streptozotocin (HFD-Fr-STZ). Rats were treated with mangiferin (20 mg/kg i.p.) for 28 days starting one week after STZ and its effects were compared to the standard insulin sensitizer, rosiglitazone. HFD-Fr-STZ, induced obesity, hyperglycemia and insulin resistance accompanied by depletion in liver glycogen and dyslipidemia. Moreover, there was an elevation in serum TNF-α and a reduction in adiponectin. Mangiferin ameliorated the consequences of HFD-Fr-STZ and its actions were comparable to the effects of the standard insulin sensitizer, rosiglitazone. The results obtained in this study provide evidence that mangiferin is a possible beneficial natural compound for type 2 diabetes and metabolic disorders associated with the metabolic syndrome. This effect is mediated through improving insulin sensitivity, modulating lipid profile and reverting adipokine levels to normal.

Key words: Mangiferin, diabetes, dyslipidemia, adipokines, insulin resistance.

INTRODUCTION
Diabetes mellitus (DM) is a metabolic disorder characterized by increased glucose level and insulin deficiency and/or defects of insulin action (Sellamuthu et al. 2013a). Insulin resistance is common with obesity and predisposes to a variety of diseases, including diabetes, dyslipidemia, hypertension and cardiovascular problems (Moller and Flier 1991). Moreover, subclinical low-grade inflammation plays an important role in the pathogenesis of insulin resistance (Pscherer et al. 2010). Furthermore, type 2 diabetes mellitus (T2DM) is associated with obesity, in particular, central adiposity (Flegal et al. 1998) and obesity is
characterized by the growth of adipose tissue due to the enlargement of the adipocyte size (hypertrophy) and number (hyperplasia) (Faust et al. 1978). Adipocytes have a major role in the etiology of insulin resistance and in the pathogenesis of diabetes (Boyle 2004). Enlarged adipocytes and monocyte-derived macrophages alter expression and secretion of adipokines favoring a pro-inflammatory state, where the production of inflammatory cytokines such as TNF-α and IL-6 are enhanced while the production of adiponectin, an anti-inflammatory adipokine, is reduced (Skurk et al. 2007). TNF-α is positively correlated with obesity and hyperinsulinemia (Kern et al. 2001). In contrast, a decrease in adiponectin level preceded the onset of diabetes in an obese insulin-resistant rodent model (Hotta et al. 2001). Additionally, adiponectin has antidiabetic properties and insulin sensitizing action (Zhou et al. 2010).

The natural C-glucoside xanthone, mangiferin is found in many plant species such as the Mangifera indica (Matkowski et al. 2013). Mangiferin has been reported to possess antidiabetic (Miura et al. 2001b), antioxidant (Sanchez et al. 2000), antitumor (Guha et al. 1996), antiviral (Yoosook et al. 2000) and immunomodulatory activities (Leiro et al. 2004). Mangiferin has been shown to have antidiabetic activity in KK/Ay mice, a genetic model of non-insulin-dependent diabetes mellitus (NIDDM) with hyperinsulinemia (Miura et al. 2001b).

The present study was designed to investigate the effects of mangiferin on a rat model of T2DM that mimics the unhealthy dietary habits as well as metabolic features of human T2DM in comparison to the standard thiazolidinedione insulin sensitizer; rosiglitazone.

MATERIALS AND METHODS

ANIMALS

Adult male Wistar rats, weighing 80-120g, were obtained from the National Research Center, Cairo, Egypt. They were kept under constant environmental conditions and had free access to normal pellet diet and water ad libitum, prior to dietary manipulation. This study was carried out in accordance with The Code of Ethics of the EU Directive 2010/63/EU for animal experiments and was approved by the Ethical Committee for Animal Handling at Zagazig University (ECAHZU).

DRUGS AND CHEMICALS

Mangiferin, Streptozotocin (STZ) and Dimethyl sulphoxide (DMSO) were purchased from Sigma (USA). Rosiglitazone maleate (Avandia®) was purchased from Smith Kline Beecham Pharmaceutical, Egypt, and Insulin (Mixtard®) was purchased from Novo Nordisk A/S, Denmark.

INDUCTION OF DIABETIC INSULIN-RESISTANT RATS

Induction of diabetic insulin-resistant rats was done according to the method described previously (Schaalan et al. 2009) with slight modification. Briefly, rats were fed 10% of their body weight with high fat diet (HFD, 14% saturated animal fat and 1% cholesterol powder, 60% carbohydrate, 21% protein, 3% fibers, 1% vitamins and minerals, (Reed et al. 2000)) and had free access to water containing 20% fructose (w/v) for 8 weeks.

At the 7th week, animals received a daily dose of dual-acting insulin (Mixtard 0.5 IU/Kg) for one week to prevent the reduction of insulin level following STZ injection (Reaven and Ho 1991) and to augment the insulin resistance mechanism (Chang et al. 1999). At this stage, animals were referred to as obese resistant rats.

At the beginning of the 8th week, rats received a single i.p. injection of a subdiabetogenic dose (Reed et al. 2000) of freshly prepared STZ (35 mg/kg) in citrate buffer (0.09M, PH 4.8) after overnight fasting (Reaven and Ho 1991, Srinivasan et al. 2005) and were given 5% glucose solution to drink during the first 24 hours after STZ administration to overcome hypoglycemia. Then the animals were fed with normal diet for the rest of the study.
EXPERIMENTAL DESIGN

One week after STZ injection, animals that fulfilled the following criteria: obesity (body weight 250 ± 20 gm), persistent blood glucose level exceeding 300 mg/dl, hyperinsulinemia, and dyslipidemia, were used in the study (diabetic resistant rats, HFD-Fr-STZ).

The animals were randomly allocated into 4 groups (n = 8-10): Control: rats were kept on normal diet and water during the whole study (12 weeks), Diabetic resistant rats: rats that fulfilled the previously mentioned criteria, Mangiferin: diabetic resistant rats treated with Mangiferin (20 mg/kg/day in DMSO, i.p (Muruganandan et al. 2005)) for 28 days and Rosiglitazone: diabetic resistant rats treated with rosiglitazone (4 mg/kg/day, orally in CMC (Chao et al. 2000)) for 28 days.

SAMPLING AND MEASUREMENTS

After 12 hrs of the last dose of treatment: blood was collected from the orbital sinus of rats using heparinized microcapillary tubes according to the method of (Sorg and Buckner 1964) into clean dry test tubes and centrifuged at 3700 rpm for 20 minutes, and serum was frozen at -20°C. Following, the rats were sacrificed by decapitation and livers were isolated and stored at – 80°C.

Serum glucose was determined colorimetrically using Randex reagent kit (Trinder 1969) and serum insulin concentration was estimated by radioimmunoassay (RIA) using coat -A- count insulin kit (Dalpe-Scott et al. 1982). Both insulin resistance and β-cell function were calculated by homeostasis model assessment (HOMA) (Matthews et al. 1985): Insulin resistance (HOMA-IR) = (serum glucose, mmol/L x serum insulin, μIU/ml) / 22.5 and β- Cell function = (serum insulin, μIU/ml x 20) / (serum glucose, mmol/L) – 3.5.

Triglyceride in serum and liver extracts (Bligh and Dyer 1959) were quantified usingRandex reagent kit (Fossati and Prencipe 1982), while cholesterol in serum and liver extract were measured using Randex reagent kit (Allain et al. 1974). HDL-Cholesterol was measured in fresh serum (Lopes-Virella et al. 1977), and serum LDL-C was calculated from the following formula (Friedewald et al. 1972): LDL-C (mg/dl) = TC - [HDL-C + (TG/5)], while atherogenic index was calculated from the following formula (Sagud et al. 2009): Atherogenic index = LDL-C / HDL-C

The liver glycogen was determined using EnzyChromTM Glycogen Assay Kit (Murat and Serfaty 1974).

Serum TNF-α and adiponectin were determined using solid phase Enzyme Linked Immuno Sorbent Assay (ELISA) using rat TNF-α kits (Markham et al. 1995) and rat adiponectin kit (Risch et al. 2006).

STATISTICAL ANALYSES

Data are expressed as mean ± standard error of the mean (S.E.M.). Statistical analysis was performed using one way analysis of variance (ANOVA) followed by Tukey’s post Hoc test using Graph pad Prism software version 5. For all analyses, the level of statistical significance was set at P < 0.05.

RESULTS

EFFECTS OF TREATMENT ON BODY WEIGHT, SERUM GLUCOSE, INSULIN, HOMA-IR AND B-CELL FUNCTION

Fig. 1a illustrates that the current dietary model resulted in a significant increase in body weight in diabetic resistant rats compared to control rats (244.5 ± 8.31 vs 102.9 ± 3.09 g, at P < 0.05). However, treatment with mangiferin and rosiglitazone did not cause any change in body weight in comparison to diabetic resistant group.

Fig. 1b demonstrates a significant increase in glucose level in diabetic resistant rats in comparison to control rats (244.5 ± 8.31 vs 102.9 ± 3.09 g, at P < 0.05). However, treatment with mangiferin and rosiglitazone did not cause any change in body weight in comparison to diabetic resistant group.

Fig. 1b demonstrates a significant increase in glucose level in diabetic resistant rats in comparison to control rats (316 ± 5.34 vs 82.73 ± 2.66 mg/dl, at P < 0.05). Treatment with mangiferin and rosiglitazone resulted in a significant reduction in the serum glucose level in comparison to diabetic resistant group (134.8 ± 1.44, and 115.8 ± 1.42 respectively vs 316 ± 5.34 mg/dl, at P < 0.05) (Fig. 1b).
These changes in glucose level were accompanied by a significant elevation in insulin level in diabetic resistant rats compared to normal rats (24.12 ± 0.41 vs 2.56 ± 0.05 μIU/dl, at P < 0.05). Treatment with mangiferin, or rosiglitazone failed to cause any significant change in serum insulin level compared to diabetic resistant group (Fig. 1c).

The HOMA-IR was significantly increased in diabetic resistant rats when compared to control rats (19.01 ± 0.34 vs 0.54 ± 0.01, at P < 0.05) (Fig. 1d). Treatment with mangiferin, or rosiglitazone was effective in trimming down insulin resistance in comparison to diabetic resistant rats (6.83 ± 0.15 and 4.95 ± 0.15 respectively vs 19.01 ± 0.34, at P < 0.05) (Fig. 1d).

β-cell function was not significantly changed in diabetic resistant rats when compared to that of the control group although a reduction was observed (Fig. 1e). Treatment with mangiferin or rosiglitazone increased β-cell function as compared with diabetic resistant group (103.4 ± 1.65 and 118.5 ± 3.1 respectively vs 34.19 ± 1.39, at P < 0.05).

The changes in these parameters during the induction of the model (4 weeks HFD-Fr and obese resistant rats) are presented in Figure S1 (Supplementary material).

**EFFECTS OF TREATMENT ON SERUM LIPID PROFILE**

Fig. 2a shows that diabetic resistant rats had significantly higher serum triglycerides compared to control group (170.4 ± 1.11 vs 48.25 ± 1.31 mg/dl, at P < 0.05). Treatment with mangiferin or rosiglitazone caused a significant reduction in serum triglycerides compared with diabetic resistant group (113.9 ± 1.24 and 103.7 ± 1.97 respectively vs 170 mg/dl, at P < 0.05).

Similarly, there was a significant escalation in serum cholesterol level in diabetic resistant rats compared to control rats (224.5 ± 2.34 vs 84.25 ± 0.79 mg/dl, at P < 0.05). After treatment with mangiferin or rosiglitazone, a significant fall in serum cholesterol level was observed compared with diabetic resistant group (166.6 ± 1.7 and 153.8 ± 1.16 respectively vs 224.5 ± 2.34 mg/dl, at P < 0.05) (Fig. 2b).

We also observed a significant elevation in LDL level in diabetic resistant rats compared to control group (174.2 ± 2.42 vs 33.78 ± 1.06 mg/dl, at P < 0.05), while treatment with mangiferin or rosiglitazone caused a significant decrease in LDL when compared with diabetic resistant rats (103.3 ± 1.58 and 88.6 ± 1 respectively vs 174.2 ± 2.42 mg/dl, at P < 0.05) (Fig. 2c).

The serum level of HDL dropped significantly in diabetic resistant rats compared to control group (20.67 ± 0.34 vs 48.63 ± 1.74 mg/dl, at P < 0.05), while treatment with mangiferin or rosiglitazone caused a significant elevation in HDL when compared with diabetic resistant rats (39.38 ± 0.46 and 44.5 ± 0.88 respectively vs 20.67 ± 0.34 mg/dl, at P < 0.05) (Fig. 2d).

Accordingly, the atherogenic index in diabetic resistant rats was increased compared to control rats (8.45 ± 0.23 vs 0.699 ± 0.03, at P < 0.05) and was improved by treatment with mangiferin or rosiglitazone (2.65 ± 0.07 and 1.98 ± 0.06 respectively vs 8.45 ± 0.23, at P < 0.05) (Fig. 2e).

The changes in these parameters during the induction of the model (obese resistant rats) are presented in Figure S2.

**EFFECT OF TREATMENT ON LIVER LIPID PROFILE AND GLYCOGEN CONTENT**

Diabetic resistant rats had a significantly higher level of liver triglycerides compared to control rats (12.72 ± 0.1 vs 3.48 ± 0.09 mg/g, at P < 0.05), while, treatment with mangiferin or rosiglitazone caused a significant reduction in the liver TGs compared with the diabetic resistant group (8.2 ± 0.07 and 7.23 ± 0.1 respectively vs 12.72 ± 0.1 mg/g, at P < 0.05) (Fig. 3a).

Liver cholesterol content was significantly higher in diabetic resistant rats compared to control rats (14.85 ± 0.11 vs 4.73 ± 0.09 mg/g, at P < 0.05), while, treatment with mangiferin, or rosiglitazone caused a significant reduction in the liver cholesterol content compared with the diabetic resistant group.
Figure 1 - Effect of HFD-Fr-STZ and treatment with mangiferin (20 mg/kg/IP) and rosiglitazone (4 mg/kg/orally) on: a) body weight, b) serum glucose level (mg/dl), c) serum insulin level (µIU/ml), d) HOMA-IR and e) β-cell function. Data are presented as mean ± S.E.M (n=8-10). * Significantly different from control group, # Significantly different from diabetic resistant group at P < 0.05 using one-way ANOVA followed by Tukey's post Hoc test.

In contrast, liver glycogen content was significantly depleted in diabetic resistant rats compared to control rats (1.83 ± 0.04 vs 6.28 ± 0.13 mg/g, at P < 0.05) (Fig. 3b).

(11.37 ± 0.08 and 12.81 ± 0.09 respectively vs 14.85 ± 0.11 mg/g, at P < 0.05) (Fig. 3b).

In contrast, liver glycogen content was significantly depleted in diabetic resistant rats compared to control rats (1.83 ± 0.04 vs 6.28 ± 0.13 mg/g, at P < 0.05), while, treatment with mangiferin or rosiglitazone caused a significant elevation in the liver glycogen content compared with the diabetic resistant group (2.64 ± 0.09 and 2.33 ± 0.03 respectively vs 1.83 ± 0.04 mg/g) (Fig. 3c).
The serum level of TNF-α was significantly increased in diabetic resistant rats compared with control group (256.2 ± 2.98 vs 16.5 ± 0.67 pg/ml, at P < 0.05), while, treatment with mangiferin or rosiglitazone significantly reduced serum TNF-α compared with the diabetic resistant group (121.8 ± 0.45 and 133.2 ± 0.47 respectively vs 256.2 ± 2.98 pg/ml, at P < 0.05) (Fig. 4a).

On the other hand, adiponectin level significantly declined in diabetic resistant group compared with control group (0.95 ± 0.04 vs 3.85 ± 0.04, at P < 0.05) (Fig. 4b).

**Figure 2** - Effect of HFD-Fr-STZ and treatment with mangiferin (20 mg/kg/IP) and rosiglitazone (4 mg/kg/orally) on: a) serum TG level (mg/dl), b) serum TC level (mg/dl), c) serum LDL-C level (mg/dl) d) serum HDL-C level (mg/dl) and e) atherogenic index. Data are presented as mean ± S.E.M (n=8-10). * Significantly different from control group, # Significantly different from diabetic resistant group at P < 0.05 using one-way ANOVA followed by Tukey’s post Hoc test.

**Effects of Treatment on Serum Adipokines**
The serum level of TNF-α was significantly increased in diabetic resistant rats compared with control group (256.2 ± 2.98 vs 16.5 ± 0.67 pg/ml, at P < 0.05), while, treatment with mangiferin or rosiglitazone significantly reduced serum TNF-α compared with the diabetic resistant group (121.8 ± 0.45 and 133.2 ± 0.47 respectively vs 256.2 ± 2.98 pg/ml, at P < 0.05) (Fig. 4a). On the other hand, adiponectin level significantly declined in diabetic resistant group compared with control group (0.95 ± 0.04 vs 3.85 ± 0.04, at P < 0.05) (Fig. 4b).
Mangiferin in Diabetes and Dyslipidemia

± 0.14 ng/ml, at P < 0.05), while, treatment with mangiferin, or rosiglitazone caused a significant increase in serum adiponectin compared with the diabetic resistant group (2.32 ± 0.03, and 2.15 ± 0.02 respectively vs 0.95 ± 0.4 ng/ml, at P < 0.05) (Fig. 4b).

The changes in these parameters during the induction of the model (obese resistant rats) are presented in Figure S3.

**DISCUSSION**

Insulin resistance is a common feature of obesity and predisposes the affected individuals to a variety of diseases, including T2DM, dyslipidemia, hypertension and cardiovascular problems (Moller and Flier 1991).

In the present study, a rat model that mimics a typical unhealthy dietary habit as well as metabolic features of human T2DM (Aguila and Mandarim-de-Lacerda 2003) was chosen. This model resulted in an increase in body weight, hyperglycemia, hyperinsulinemia and insulin resistance as reflected by elevated HOMA-IR. Similar results were previously reported in this model (Schaalan et al. 2009) and the resulting disorders closely mimic the metabolic features of human T2DM (Axelsen et al. 2010). In addition, this model resulted in a state of hyperlipidemia (elevation of serum triglycerides, cholesterol, LDL-C, atherogenic index and reduction in HDL-C) and triglycerides and cholesterol accumulated in the liver associated with
a reduction in liver glycogen content as supported by previous studies (Schaalan et al. 2009). This state is equivalent to the so called hepatic steatosis (Brewer 1999, Festi et al. 2004) or nonalcoholic steatohepatitis (NASH) (Puri et al. 2009). Clinical characteristics associated with hepatic steatosis include obesity, hyperlipidemia and diabetes mellitus, all of which have been partly attributed to insulin resistance (Harrison et al. 2002).

Fat accumulation in the liver was previously reported to be associated with impaired insulin clearance and hyperinsulinemia (Lim et al. 2009). Long term HFD-Fr was reported to upregulate the expression of hepatic sterol regulatory element binding protein (SREBP-1) and decrease the expression of PPAR-α receptor (Aragno et al. 2009). PPAR-α activation mediates expression of genes regulating lipid oxidation (Kersten et al. 2000). These results support the findings of the current study.

The current model, in addition, presented a decrease in adiponectin and an increase in TNF-α in diabetic resistant rats. Low adiponectin levels are found in insulin resistant states, such as obesity, diabetes mellitus and ischaemic heart disease (Hotta et al. 2000). It produces its action by binding to adiponectin receptor 1 and 2 expressed in the liver and skeleton muscle (Yamauchi et al. 2003) and activates PPAR-α and AMP-activated protein kinase (AMPK), thus enhancing insulin sensitivity and exerting anti-inflammatory action in NASH (Liu et al. 2011). Adipose tissues also produce TNF-α (Bastard et al. 2006), which inhibits insulin-stimulated glucose uptake by adipose tissues and skeletal muscle and in turn, causes insulin resistance (Hotamisligil et al. 1993) in rodents. Therefore, the elevated levels of TNF-α in the current study may have led to the induction of insulin resistance and is, in part, responsible for hepatic fatty changes (Lonardo et al. 2005).

Herbal remedies are apparently efficient, produce the least or no harmful effects in clinical experience, and are comparatively of low costs as compared to oral synthetic antidiabetic agents (Hung et al. 2012). Nowadays, natural therapies gain importance as they have been shown to regulate complications of diabetes (Arulselvan and Subramanian 2007).

In this study, treatment with mangiferin restored the disturbed glucose homeostasis and improved insulin sensitivity as indicated by the HOMA-IR and β-cell function, indicating that it can improve insulin resistance. Similar actions of mangiferin...
Mangiferin was previously reported (Sellamuthu et al. 2014). Mangiferin was reported to decrease oxidative stress and pancreatic β-cell damage in streptozotocin-induced diabetes in rats (Sellamuthu et al. 2013b).

Different mechanisms have been proposed for the hypoglycemic effect of mangiferin. These include enhancement of insulin release/secretion (insulinotropic effect) (Jouad et al. 2000), stimulation of peripheral glucose utilization, enhancing glycogenic process with concomitant decrease in glycogenolysis and gluconeogenesis (Saxena and Vikram 2004). Furthermore, it is also likely that it might reduce blood glucose level by inhibiting glucose absorption from the intestine because mangiferin inhibits α-glucosidase enzymes (Yoshikawa et al. 2001) which are involved in the digestion of carbohydrate into simple sugars in the gut leading to delay or inhibition of carbohydrate breakdown and subsequent glucose absorption from the intestine (Emilien et al. 1999). A similar observation was previously reported after intraperitoneal administration of mangiferin in streptozotocin diabetic rats (Muruganandan et al. 2005) which was attributed to the enterohepatic circulation.

In addition, mangiferin was able to correct the disturbed lipid profile in serum and liver. Similar effects of mangiferin in improving dyslipidemia were previously reported in streptozotocin diabetic rats (Guo et al. 2011, Muruganandan et al. 2005). Mangiferin may mediate its action on lipid profile through increasing fatty acid uptake in the liver via upregulation of the expression of fatty acid translocase (Guo et al. 2011), downregulation of microsomal triglyceride transfer protein (MTP) and upregulation of hepatic PPAR-α expression (Guo et al. 2011). According to the Randle’s glucose–fatty acid cycle, increased plasma triglycerides and increased free fatty acid (FFA) oxidation impairs insulin action, glucose metabolism and utilization leading to hyperglycemia and consequently, reduction of triglycerides could participate to the hypoglycemic effect of mangiferin (Randle et al. 1963).

As mentioned earlier, inflammatory pathways hold a substantial role in insulin resistance in type 2 diabetes. Therefore, diabetes therapy should not focus only on glycemic control but also on mechanisms to control inflammation and hence improve insulin resistance.

In the present study, mangiferin caused a reduction of serum TNF-α and an elevation of serum adiponectin production which may be attributed to activation of PPAR-γ as mentioned earlier (Giron et al. 2009), which is known to induce the expression of adiponectin (Iwaki et al. 2003). Furthermore, previous reports have demonstrated the ability of mangiferin to block the expression of TNF-α (Leiro et al. 2004). The suppression of TNF-α is known to cause activation of PP-1 allowing insulin to activate glycogen storage (Ragolia and Begum 1998), and reduction of FFA availability resulting in inhibition of both gluconeogenesis and glycogenolysis (Ruan et al. 2003) and reduction in the availability of FFAs for synthesis of VLDL (Yoon et al. 2006). On the other hand, the elevation of adiponectin activates GSK3β, a key molecule involved in regulating glycogen homeostasis (Zhou et al. 2010). The mechanisms by which adiponectin ameliorates insulin sensitivity include increased peripheral glucose uptake and suppressed hepatic glucose production (Lim et al. 2009).

Mangiferin was previously shown to have no action on blood glucose level in normal rats (Miura et al. 2001a, Muruganandan et al. 2005) and it was also shown not to modify insulin secretion from isolated pancreatic islets from healthy Wistar rats (Hoa et al. 2004). However, the effects of mangiferin on serum and liver lipid profile was not tested in normal rats before and needs to be investigated in future research.

Concerning the reference drug, rosiglitazone corrected the disturbed lipid profile in serum and liver. A previous study has shown that rats treated with rosiglitazone had lower serum TGs, insulin, liver TGs associated with elevation in
liver glycogenesis (Seda et al. 2002). Clinically, rosiglitazone is able to reduce steatosis and transaminase levels in NASH patients (Ratziu et al. 2008) and these changes were associated with elevation in adiponectin level (Holguin et al. 2007). Finally, rosiglitazone attenuated the disturbed secretion of TNF-α and adiponectin. This confirms earlier work displaying that TNF-α was markedly decreased and adiponectin receptor expression was attenuated by rosiglitazone (Liu et al. 2011).

CONCLUSION
The present study has demonstrated the beneficial effect of mangiferin in HFD-Fr-STZ-treated rats, a model that mimics most of the metabolic features of human T2DM. These actions were comparable to the standard insulin sensitizer, rosiglitazone indicating the possible clinical impact of mangiferin in type-2 diabetic patients. Based on the results of the current study, the effects of mangiferin might be attributed to its ability to correct the disturbed level of serum adipokines resulting in a reduction in TNF-α and an elevation in adiponectin which is expected to improve insulin action leading to better glycemic control and correct the disturbed lipid profile in both serum and liver. However, other mechanisms might be involved in mediating these actions of mangiferin and require further investigation. In addition, the possible use of mangiferin against diabetic complications seems a promising target. The authors declare that they have no conflict of interest.

ACKNOWLEDGMENTS
The authors would like to acknowledge Zagazig University funding program (8K2/M3, 2009) for partially funding Dr. Waleed Barakat.

RESUMO
Foi verificado que a mangiferina, presente na casca de Mangifera indica, apresenta atividade hipoglicemiante e antidiabética em um modelo animal de diabetes tipo 2 de origem genética e em ratos diabéticos tratados com estreptozotocina (STZ). Seu efeito em animais diabéticos resistentes à insulina ainda não foi investigado. O presente trabalho objetivou explorar o efeito de mangiferina em ratos diabéticos resistentes à insulina. O quadro diabético foi induzido por uma dieta com alto conteúdo de gordura e frutose por oito semanas, seguida de uma dose sub-diabetogênica de estreptozotocina (HFD-Fr-STZ). Uma semana após o tratamento com STZ os ratos foram tratados com mangiferina (20 mg/kg i.p.) por 28 dias e seus efeitos foram comparados os sensibilizador insulinérgico padrão, a rosiglitazona. A combinação HFD-Fr-STZ induziu obesidade, hiperglicemia e resistência à insulina, acompanhada por depleção de glicogênio hepático e dislipidemia. Além disso, houve uma elevação no TNF-alfa sérico e uma redução de adiponectina. A mangiferina melhorou as consequências do tratamento HFD-Fr-STZ e suas ações foram comparáveis aos efeitos do sensibilizador insulinérgico padrão, rosiglitazona. Os resultados obtidos neste estudo fornecem evidências que a mangiferina é um composto natural possivelmente benéfico para o tratamento do diabetes tipo 2 e de desordens metabólicas associadas à síndrome metabólica. Este efeito é mediado pela melhora da sensibilidade à insulina, modulando o perfil lipídico e revertendo os níveis de adipocinas à normalidade.

Palavras-chave: mangiferina, diabetes, dislipidemia, adipocinas, resistência à insulina.

REFERENCES

BASTARD JP, MAACHI M, LAGATHU C, KIM MJ, CARON M, VIDAL H, CAPEAU J AND FEVE B. 2006. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17: 4-12.


An Acad Bras Cienc (2014) 86 (4)
An Acad Bras Cienc (2014) 86 (4)


SUPPLEMENTARY MATERIAL

Figure S1 - Effect of HFD-Fr for 4 weeks (HFD-4w) and HFD-Fr for 7 weeks accompanied by a daily dose of insulin (0.5 IU/kg) during the 7th week (Obese resistant rats) on: a) body weight, b) serum glucose level (mg/dl), c) serum insulin level (µIU/ml), d) HOMA-IR and e) β-cell function. Data are presented as mean ± S.E.M (n=8-10). * Significantly different from control group, # Significantly different from diabetic resistant group at P < 0.05 using one-way ANOVA followed by Tukey's post Hoc test.

Figure S2 - Effect of HFD-Fr for 7 weeks accompanied by a daily dose of insulin (0.5 IU/kg) during the 7th week (Obese resistant rats) on: a) serum TG level (mg/dl), b) serum TC level (mg/dl), c) serum LDL-C level (mg/dl) d) serum HDL-C level (mg/dl) and e) atherogenic index. Data are presented as mean ± S.E.M (n=8-10). * Significantly different from control group, # Significantly different from diabetic resistant group at P < 0.05 using one-way ANOVA followed by Tukey's post Hoc test.

Figure S3 - Effect of HFD-Fr for 7 weeks accompanied by a daily dose of insulin (0.5 IU/kg) during the 7th week (Obese resistant rats) on: a) serum TNF-α level (pg/ml) and b) serum adiponectin level (ng/ml). Data are presented as mean ± S.E.M (n=8-10). * Significantly different from control group, # Significantly different from diabetic resistant group at P < 0.05 using one-way ANOVA followed by Tukey's post Hoc test.